33M

Globally 33 million young children are diagnosed with RSV disease each year.

3-6%

Between 3-6% of all older adults are infected with RSV every year.

118K

Annually, RSV causes an estimated 118,000 child deaths worldwide.

5B

Childhood RSV costs governments around the world nearly 5 billion € every year.

Subscribe to our newsletter

We will process your data to deliver our updates to your inbox. 
You can view our Privacy Policy here or contact us at info@imi-promise.eu for more information.

A joint effort to reach further

Scientists from academia and the pharmaceutical/biotechnology industry, clinicians, public health agencies, patient groups, and clinical societies have come together to share knowledge on RSV and foster scientific debate to advance on the development of preventive solutions that contribute to lessen RSV disease burden.

Factsheet

Our ambition

PROMISE (Preparing for RSV Immunisation and Surveillance in Europe), an IMI funded project, kicked off November 1st, 2021, with the objective of taking a major leap forward in the fight against Respiratory Syncytial Virus (RSV) in Europe and worldwide.

This initiative builds on RESCEU’s (Respiratory Syncytial Virus Consortium in Europe) achievements, another IMI project focused on generating insights into the impact of RSV on healthcare systems and society. PROMISE takes over RESCEU with the mission to continue advancing scientific knowledge on RSV to better inform public health strategies and to support the development and introduction of novel immunisations tools and therapeutics against this potentially deadly virus in the paediatric and elderly populations.

Learn more

Latest updates

  • Thursday, February 15, 2024

    News

    Read the full systematic review published in The Lancet this February 2024 and learn about the top 3 findings.

22 Partners in Europe

Partners
TEAMIT FISABIO SERGAS PENTA Sanofi UEDIN TUCH THL Pfizer Imperial UOXF MLU RIVM UMCU ReSVINET NIVEL SSI JANSSEN GSK UA Novavax AZ